🔗 Share this article

The recently developed medications for gonorrhoea in decades are being described as a "significant breakthrough" in the battle against superbug strains of the pathogen, according to scientists.

An International Challenge

Gonorrhoea infections are on the rise worldwide, with estimates suggesting more than 82 million instances annually. Notably increased rates are observed in Africa and nations within the WHO's Western Pacific region, which spans from China and Mongolia to New Zealand. Within England, cases have reached a record high, while rates across Europe in 2023 were three times higher compared to figures for 2014.

“The clearance of novel therapies for gonorrhoea is an critical and opportune development in the face of increasing worldwide cases, escalating drug resistance and the highly restricted available drugs currently available.”

Health officials are increasingly worried about the surge in treatment-resistant strains. The global health body has listed it as a "critical concern". Recent surveillance showed that the effectiveness of standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Treatment Options Gain Approval

Zoliflodacin, alternatively called Nuzolvence, was cleared by the US FDA in December for treating gonorrhoea. This STI can lead to major issues, including the inability to conceive. Experts believe that specific application of this new drug will help hinder the emergence of superbugs.

Gepotidacin, developed by the drugmaker GSK, was also approved in concurrent days. This drug, which is also used to treat UTIs, was demonstrated in studies to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Novel Development Model

This new treatment was the result of a unique collaborative effort for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company Innoviva to bring it to fruition.

“This authorization marks a significant shift in the management of superbug gonorrhoea, which until now has been staying ahead of medical innovation.”

Clinical Trial Outcomes and Worldwide Availability

As per findings published in a prominent scientific publication, the new drug successfully treated the vast majority of genital gonorrhoea infections. This places it at an equal footing with the typical regimen, which involves an injection and a pill. The trial included nearly 1,000 volunteers from several countries including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its collaboration, the non-profit has the rights to license and sell the drug in numerous regions with limited resources.

Doctors directly involved have shared optimism. Having a single-dose, oral treatment like this is seen as a "game-changer" for gonorrhoea control. This is viewed as crucial to alleviate the strain of the illness for individuals and to halt the transmission of highly drug-resistant gonorrhoea worldwide.